Immune Pharmaceuticals changes board of directors
Thursday, October 17, 2013
Immune Pharmaceuticals has announced that Rene Lerer, M.D., executive chairman of Magellan Health Services, and Daniel Kazado, senior advisor to Melini Capital, have joined the company’s board of directors. Lerer and Kazado replace Pierre Albouy and Herve de Kergrohen, who have resigned from the board but will continue as strategic advisors to the company. The board will continue to consist of seven members.
Lerer is a healthcare leader with more than 30 years of experience. For the past decade, he has lead Magellan Health Services, first as president and chief operating officer before being named chairman and CEO. He operationally and financially transformed Magellan into a specialty health care company with revenue of more than $3 billion and a market cap of over $1.5 billion. Lerer’s experience also includes founder and president of the Internet Healthcare Group, chief operating officer of Prudential Healthcare and senior executive positions with Value Health, Value Health Sciences and The Travelers Companies.
Kazado is a senior advisor to Melini Capital, a family owned private and public equity firm investing internationally in several industries. Melini Capital has been an early and significant investor in Immune Pharmaceuticals. Kazado built his own management consulting firm over 15 years to 25 professionals advising boards of directors and senior management in multiple industries, and in 2002 sold the company to Altran Technologies, a global engineering and management consulting group.